JP2021527031A5 - - Google Patents

Info

Publication number
JP2021527031A5
JP2021527031A5 JP2020566701A JP2020566701A JP2021527031A5 JP 2021527031 A5 JP2021527031 A5 JP 2021527031A5 JP 2020566701 A JP2020566701 A JP 2020566701A JP 2020566701 A JP2020566701 A JP 2020566701A JP 2021527031 A5 JP2021527031 A5 JP 2021527031A5
Authority
JP
Japan
Prior art keywords
cocrystal
pharmaceutically acceptable
acceptable salt
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566701A
Other languages
English (en)
Japanese (ja)
Other versions
JP7778477B2 (ja
JP2021527031A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034505 external-priority patent/WO2019232120A1/en
Publication of JP2021527031A publication Critical patent/JP2021527031A/ja
Publication of JP2021527031A5 publication Critical patent/JP2021527031A5/ja
Priority to JP2024030700A priority Critical patent/JP7841008B2/ja
Application granted granted Critical
Publication of JP7778477B2 publication Critical patent/JP7778477B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566701A 2018-05-30 2019-05-30 セピアプテリンの薬学的に許容される塩 Active JP7778477B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024030700A JP7841008B2 (ja) 2018-05-30 2024-02-29 セピアプテリンの薬学的に許容される塩

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862678025P 2018-05-30 2018-05-30
US62/678,025 2018-05-30
US201862726612P 2018-09-04 2018-09-04
US62/726,612 2018-09-04
US201962822336P 2019-03-22 2019-03-22
US62/822,336 2019-03-22
GC2019/37661 2019-05-28
GC201937661 2019-05-28
PCT/US2019/034505 WO2019232120A1 (en) 2018-05-30 2019-05-30 Pharmaceutically acceptable salts of sepiapterin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024030700A Division JP7841008B2 (ja) 2018-05-30 2024-02-29 セピアプテリンの薬学的に許容される塩

Publications (3)

Publication Number Publication Date
JP2021527031A JP2021527031A (ja) 2021-10-11
JP2021527031A5 true JP2021527031A5 (enExample) 2022-06-07
JP7778477B2 JP7778477B2 (ja) 2025-12-02

Family

ID=68699017

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566701A Active JP7778477B2 (ja) 2018-05-30 2019-05-30 セピアプテリンの薬学的に許容される塩
JP2024030700A Active JP7841008B2 (ja) 2018-05-30 2024-02-29 セピアプテリンの薬学的に許容される塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024030700A Active JP7841008B2 (ja) 2018-05-30 2024-02-29 セピアプテリンの薬学的に許容される塩

Country Status (13)

Country Link
US (1) US20210269443A1 (enExample)
EP (1) EP3807279B1 (enExample)
JP (2) JP7778477B2 (enExample)
KR (1) KR20210038848A (enExample)
CN (1) CN112543758A (enExample)
AU (2) AU2019277372B2 (enExample)
BR (1) BR112020024332A2 (enExample)
CA (1) CA3102070A1 (enExample)
CL (1) CL2020003101A1 (enExample)
CO (1) CO2020016582A2 (enExample)
IL (1) IL279101A (enExample)
MX (1) MX2020012978A (enExample)
WO (1) WO2019232120A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) * 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
AU2019277372B2 (en) * 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
EP4093405A1 (en) 2020-01-24 2022-11-30 PTC Therapeutics MP, Inc. Methods for treating parkinson's disease with sepiapterin
CN114621198B (zh) 2020-12-11 2025-01-21 北京夏禾科技有限公司 有机电致发光材料及其器件
IL305037A (en) 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
WO2022173823A1 (en) 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
EP0722731B1 (en) * 1994-08-05 2002-06-05 Suntory Limited Remedy for spinocerebellar degeneration
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
LT2545939T (lt) * 2007-04-11 2021-03-10 Biomarin Pharmaceutical Inc. Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
EP2562176B1 (en) * 2010-04-22 2018-08-15 Nihon University Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same
CN104736539B (zh) * 2012-05-07 2017-09-01 白鸟制药株式会社 墨蝶呤和四氢乳酰蝶呤的制造法
EP3468534A4 (en) * 2016-06-13 2020-02-05 Meharry Medical College MODULATION OF THE NITROGEN OXIDE SYNTHASE SIGNAL PATH FOR ORAL HEALTH
MA46973A (fr) * 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) * 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) * 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin

Similar Documents

Publication Publication Date Title
JP2021527031A5 (enExample)
JP2024063143A5 (enExample)
ZA202001390B (en) Crystalline forms
KR102425226B1 (ko) Jak 저해제를 포함하는 제약 조성물
JP6568274B2 (ja) ニトロカテコールの投与計画
AU2025213591A1 (en) Methods of treating neurological and psychiatric disorders
JP2016503010A5 (enExample)
JP2014037426A5 (enExample)
JP5666910B2 (ja) 認知機能障害を治療するためのキット、組成物、製品もしくは医薬
JP2021525729A5 (enExample)
JP2015500236A5 (enExample)
HRP20231533T1 (hr) Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave
JP2015509534A5 (enExample)
JP2022502500A5 (enExample)
JP2015509972A5 (enExample)
JP2017538753A5 (enExample)
JP2013506670A5 (enExample)
EP3519416B1 (en) Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use
JP2018537513A5 (enExample)
JP2015500223A5 (enExample)
JP5124471B2 (ja) 置換二環式ピリミドン誘導体
JP2015522037A5 (enExample)
JP2024160326A (ja) Ｅａａｔ２活性化因子およびその使用方法
WO2012031383A1 (zh) 酰胺类化合物
IL292466B2 (en) Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(adp-ribose) polymerase-1-related diseases, comprising the same as active ingredient